Rough Draft Atlanta on MSN1d
Researchers expect FDA to approve a twice-yearly shot that reduces risk of HIV infection by 96%Roughly 61,000 Georgians live with HIV, the sexually transmitted virus (STI) that can lead to AIDS, and Atlanta ranks in the ...
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...
Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...
The post appears to reference the drug lenacapavir, which reportedly can cost around $40,000 annually in the U.S. and is administered in twice-yearly doses. While the drug appears to be effective ...
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
Uganda is registering around 38,000 new infections despite the deployment of different interventions such as condoms and oral ...
(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback